Sign in to view more
Sign in to view more
Seb Ourselin is Director of the newly founded Wellcome / EPSRC Centre for Surgical and Interventional Sciences. He is currently Vice-Dean (Health) at the Faculty of Engineering Sciences, Director of the Institute of Healthcare Engineering and of the EPSRC Centre for Doctoral Training in Medical Imaging, Head of the Translational Imaging Group within the Centre for Medical Image Computing (CMIC) and Head of Image Analysis at the Dementia Research Centre (DRC). He has published over 400 articles and raised over £40M as Principal Investigator. He is an associate editor for IEEE Transactions on Medical Imaging, Journal of Medical Imaging, Nature Scientific Reports, and Medical Image Analysis. He has been active in conference organisation (12 international conferences as General or Program Chair) and professional societies (APRS, MICCAI). He was elected Fellow of the MICCAI Society in 2016. Before joining UCL, he founded and led the CSIRO BioMedIA Lab, Australia. He led the imaging research programme of the AIBL study and of a successfully commercialized colonoscopy simulator. He leads the translational imaging research programme between CMIC and the National Hospital for Neurology and Neurosurgery. He has established with Prof. Nick Fox a new imaging unit to deliver engineering solutions for clinical trials. With Prof. John Duncan, he leads the development of an image-guided neurosurgery platform, deployed within the iMRI environment for temporal lobe epilepsy. This work built the foundation for expanding into neurosurgical planning (HICF). He is also leading the development of the open-source NifTK platform (>20,000 downloads). Most of these activities are underpinning GIFT-Surg’s technological foundations, an Innovative Engineering for Health grant funded by the Wellcome Trust and EPSRC. In 2015, he founded a UCL spin-out company aiming at delivering automatic quantitative imaging through PACS-embedded clinical reports (Brainminer Limited). The company has raised so far over £1M through SBRI by leveraging a uniquely patented technology enabling robust brain parcellation.